Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

In the previous phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune therapy. The current study builds on this work, and will explore different 4-dose treatment regimens, which are designed to enhance the patients' response and determine the best therapeutic approach. During the study, patients will receive a controlled dose of cat allergen in an environmental exposure chamber both before and after treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the different treatment regimes. The double-blind, randomized, placebo-controlled trial will include a total of 120 volunteers with confirmed cat allergies. The study, which is already underway in Canada, is progressing well with approximately 20% of patients enrolled for screening so far.

"This study is of great importance for Circassia as it is designed to define the most effective treatment regime for our ToleroMune allergy products, and in particular for the phase III studies of our cat-allergy therapy that are planned to begin in the second half of 2009," said Steve Harris, Circassia's CEO. "The results of our trials to date show that our ToleroMune approach offers patients substantial potential benefits. Conventional allergy treatments either address symptoms only or require many doses over a period of months under specialist supervision because they can result in serio
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... YORK , July 7 Reportlinker.com announces that a new market research ... , Stakeholder ... , , , ... , , ...
... July 7 Scientists have used a genetically reprogrammed herpes virus ... metastatic disease in mice – still an elusive goal when treating humans ... Gene Therapy. , ... Less than 30 percent of patients with metastatic cancer survive ...
Cached Medicine Technology:Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 2Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 3Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 4Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 5Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 6Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 7Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 8Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 9Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 10Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 11Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 12Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 13Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 14Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 2Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 3Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 4
(Date:9/1/2014)... September 02, 2014 Renal cell carcinoma (RCC) ... lining of the proximal convoluted tubule, a part of the ... from the blood to the urine. The condition is asymptomatic ... RCC are often in the advanced stages of the disease ... RCC often include blood in the urine, flank pain, a ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... Recent surveys from,Centers for Disease Control and ... Epidemiology (APIC) have raised awareness of the,threat ... Staphylococcus aureus (MRSA). As the public learns,more ... simple steps,to protect themselves and loved ones ...
... NGSX ), a biopharmaceutical company focused on developing ... results for its third quarter of 2007 on Wednesday, ... call to review the results will begin at 4:30 ... will be hosted by Anthony DiTonno,President and Chief Executive ...
... overwhelming majority, 90 percent of Americans, claim a particular ... religiously diverse than ever before, which is why it ... clients beliefs stem from, says Dr. E. Thomas Dowd, ... much less religious than the general population, says Dowd. ...
... Commonwealth University researchers have discovered a new mechanism to ... clotting disorders, which could lead to novel therapies to ... in the body in areas such as the legs. ... a protein involved in coagulation, is inhibited, rendering blood ...
... - Request Provides CMS with New Scientific ... Ortho Biotech Products, L.P.,the company that ... that the Centers for Medicare and Medicaid ... (NCD) for,erythropoiesis-stimulating agents (ESAs). The company,s request ...
... the Washington,state man who,s spent more than a year walking ... to conclude his odyssey,today at the southernmost city in the ... Gregory set out from his home near the Canadian,border in ... job,with a beverage distributor to accommodate his plans. His trek ...
Cached Medicine News:Health News:Six Simple Steps to Protect Against and Stop the Spread of Superbugs 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 3Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 3Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 4Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 5Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
... The BacT/Alert 3D Select is ... automated microbial detection system that ... and mycobacteria culturing. This system ... management or laboratory information system ...
Medicine Products: